Go Pro
NASDAQ:AZTA

Azenta Q3 2026 Earnings Report

Azenta logo
$24.51 -0.86 (-3.39%)
Closing price 04:00 PM Eastern
Extended Trading
$24.33 -0.18 (-0.73%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Azenta EPS Results

Actual EPS
N/A
Consensus EPS
$0.10
Beat/Miss
N/A
One Year Ago EPS
N/A

Azenta Revenue Results

Actual Revenue
N/A
Expected Revenue
$149.29 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Azenta Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call Date
Tuesday, August 4, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Azenta Earnings Headlines

Azenta Completes Sale of B Medical Systems
Azenta Acquires UK Biocentre to Expand European Biorepository
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
See More Azenta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Azenta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azenta and other key companies, straight to your email.

About Azenta

Azenta (NASDAQ:AZTA) (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services. Researchers and biopharma companies rely on these capabilities for applications ranging from basic research and drug discovery to precision medicine. The company’s facility network supports high-throughput processing, quality control and regulatory compliance, addressing needs across genomics, transcriptomics and proteomics workflows.

Headquartered in Chelmsford, Massachusetts, Azenta serves a global customer base that includes pharmaceutical and biotechnology firms, academic institutions and contract research organizations. The company operates multiple facilities across North America, Europe and Asia, enabling scalable sample management and genomics projects. Its solutions are designed to support complex supply chains for cell and gene therapies, biologics development and large-scale biobanking initiatives.

Azenta completed its spin-off from Brooks Automation in February 2021, establishing itself as a standalone public company focused on the accelerating demands of life sciences research. The company is led by President and Chief Executive Officer Joseph L. Hawkins, whose leadership team continues to expand Azenta’s footprint in sample management automation and genomics services worldwide. Through ongoing investments in technology and facility capacity, Azenta aims to drive innovation in life sciences and deliver reliable, end-to-end solutions to its customers.

View Azenta Profile